MaaT Pharma's total assets for Q2 2024 were €50.92M, an increase of 18.62% from the previous quarter. FR:MAAT total liabilities were €25.31M for the fiscal quarter, a 12.67% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.